Oncolys BioPharma submits IND application for new indication of OBP-301
Oncolys BioPharma Inc. <4588> announced after the close on June 3 that it has submitted an Investigational New Drug (IND) application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase 1b/2a clinical trial of its oncolytic virus OBP-301, targeting new indications of lower rectal and anal cancer. The study will evaluate the efficacy and safety of OBP-301 when combined with preoperative chemoradiotherapy. Oncolys plans to begin patient dosing within the fiscal year ending December 2026.
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
-
Bank of Japan exchange rate at 5 p.m.: dollar rises to 159.70-71 yen
Wed Jun 3, 2026 5:45 pm JST Currency -
Hong Kong's Hang Seng Index closes at 25,633.21 on the 3rd, down 405.11 points
Wed Jun 3, 2026 5:28 pm JST Market -
Battery storage ranks 4th as METI announces revised battery and power industry strategy
Wed Jun 3, 2026 12:20 pm JST Feature -
Tokyo stocks close 1,667 yen higher, led by semiconductor-related shares to land in 68,000 yen range
Wed Jun 3, 2026 4:18 pm JST Market -
Shanghai Composite Index closes at 4,083.9740 on the 3rd, up 8.8724 points
Wed Jun 3, 2026 4:37 pm JST Market -
Seiwa HD to acquire plating business from Mitaka Metal Industries to strengthen production capacity amid semiconductor demand growth
Wed Jun 3, 2026 4:07 pm JST Catalyst -
Nikkei 225 close on the 3rd = rebound, 1,667 yen higher to 68,402 yen
Wed Jun 3, 2026 3:32 pm JST Market -
PowerX prepares to apply for market section change to TSE Prime
Wed Jun 3, 2026 3:48 pm JST Catalyst -
WORLD CO., LTD. reports first year-on-year increase in existing store sales in three months for May
Wed Jun 3, 2026 3:44 pm JST Catalyst -
Active stocks on the 3rd (closing) - Rasa Industries, TerraSky, and ST and others
Wed Jun 3, 2026 3:32 pm JST Catalyst